TARSUS 2025 Q3
Earnings Overview & AI Insights

Earnings Performance

Summary of Financial Performance: Tarsus reported exceptional financial results for Q3 2025, with XDEMVY generating approximately $119 million in net revenue, marking double-digit growth from the previous quarter. The company shipped over 107,000 bottles to distributors and dispensed more than 103,000 bottles to patients. The gross-to-net discount was 44.7%, reflecting strong demand across a broad patient base, particularly Medicare patients. Tarsus projects Q4 net product sales of $140 million to $145 million, with annual revenue expected to reach $440 million to $445 million.

Company Outlook & Strategy: Tarsus plans to capitalize on the success of XDEMVY by expanding its pipeline with new category-creating opportunities such as treatments for ocular rosacea and Lyme disease prevention. The company is set to initiate a Phase II trial for ocular rosacea by year-end and anticipates international expansion into Europe and Japan. Tarsus aims to sustain its growth momentum into 2026 and beyond by broadening its pipeline and continuing its direct-to-consumer campaigns.

Key Industry Trends: The pharmaceutical industry sees XDEMVY as a significant breakthrough in eye care, especially for treating Demodex blepharitis (DB). The condition is becoming mainstream, with increasing diagnosis rates and treatment confidence among eye care professionals. The market is also witnessing a trend towards more frequent prescriptions, moving from monthly to weekly and daily.

Operational Highlights: Operationally, Tarsus is experiencing strong adoption of XDEMVY among eye care professionals, with significant increases in weekly prescriptions. The company's direct-to-consumer efforts have effectively driven awareness and patient demand, leading to increased office visits and prescriptions. Tarsus continues to invest in its commercial capabilities and plans to expand globally.

Challenges & Risks: Potential risks include the dynamic Medicare mix impacting the gross-to-net discount, which could affect profitability. There's also a reliance on the continued success of XDEMVY's launch and the ability to replicate this success with future products.

Key Analyst Questions & Responses:

• Analysts inquired about changes in doctors' prescribing patterns due to new data on meibomian gland disease (MGD) related to DB, which has led to broader screening and increased prescriptions.
• Questions were raised about refill rates for XDEMVY, with Tarsus noting positive trends in retreatment behavior, expecting stabilization around 20% over time.
• Analysts asked about potential updates to internal peak sales estimates for XDEMVY given its strong growth trajectory; Tarsus did not specify new estimates but expressed confidence in the product's blockbuster potential.